FrancophonIA/ELRC3.0 huggingface dataset:
English: In these patients, Erbitux is used alone or in combination with other anticancer medicines.
Croatian: Kod ovih bolesnika Erbitux se primjenjuje sam ili u kombinaciji s drugim lijekovima za liječenje karcinoma.
English: In addition, hypokalaemia may develop as a consequence of diarrhoea.
Croatian: Dodatno, kao posljedica proljeva može se pojaviti hipokalemija.
English: In vitro cetuximab inhibits the production of angiogenic factors by tumour cells and blocks endothelial cell migration.
Croatian: In vitro cetuksimab inhibira proizvodnju angiogenetskih čimbenika u tumorskoj stanici i blokira migraciju endotelne stanice.
English: In both in vitro and in vivo assays, cetuximab inhibits the proliferation and induces apoptosis of human tumour cells that express EGFR.
Croatian: I u in vitro i in vivo pokusima, cetuksimab inhibira proliferaciju i potiče apoptozu humanih tumorskih stanica koje iskazuju EGFR.
English: Do not use Erbitux
Croatian: Nemojte primjenjivati Erbitux
English: Treatment in the cetuximab arm consisted of up to 6 cycles of platinum-based chemotherapy in combination with cetuximab followed by cetuximab as maintenance therapy until disease progression.
Croatian: Liječenje u skupini s cetuksimabom sastojalo se od do 6 ciklusa kemoterapije na bazi platine u kombinaciji s cetuksimabom nakon čega slijedi cetuksimab kao terapija održavanja do progresije bolesti.
English: No conclusive data on the neutralising effect of HACAs on cetuximab is available to date.
Croatian: Do danas nisu dostupni relevantni podaci o neutralizirajućem učinku HACA na cetuksimab.
English: • blood clots in the lungs
Croatian: • krvni ugrušci u plućima
English: In vivo cetuximab inhibits expression of angiogenic factors by tumour cells and causes a reduction in tumour neo-vascularisation and metastasis.
Croatian: In vivo cetuksimab inhibira ekspresiju čimbenika angiogeneze na tumorskim stanicama i uzrokuje smanjenje tumorske neovaskularizacije i metastaziranja.
English: MARKETING AUTHORISATION NUMBERS EU/1/04/281/003
Croatian: ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/281/003
English: Of these, 362 patients received cetuximab and oxaliplatin plus fluoropyrimidines (117 patients OxMdG and 245 patients XELOX) and 367 patients received oxaliplatin plus fluoropyrimidines alone (127 patients OxMdG and 240 patients XELOX).
Croatian: Od njih, 362 bolesnika su primila cetuksimab i oksaliplatin sa fluropirimidinima (117 bolesnika OxMdG i 245 bolesnika XELOX) a 367 bolesnika su primili samo oksaliplatin i fluoropirimidine (127 bolesnika OxMdG i 240 bolesnika XELOX).
English: • For administration with infusion pump or gravity drip (diluted with sterile sodium chloride 9 mg/mL (0.9%) solution): Take an infusion bag of adequate size of sterile sodium chloride 9 mg/mL (0.9%) solution.
Croatian: • Primjena s infuzijskom pumpom ili običnom infuzijom (razrijeđen 0,9%-tnom (9 mg/ml) sterilnom otopinom natrijeva klorida): Uzmite infuzijsku vrećicu 0,9%-tne (9 mg/ml) sterilne otopine natrijeva klorida odgovarajuće veličine.
English: Cetuximab in combination with chemotherapy
Croatian: Cetuksimab u kombinaciji s kemoterapijom
English: Limited observations in animals are indicative of a placental transfer of cetuximab, and other IgG1 antibodies have been found to cross the placental barrier.
Croatian: Ograničena opažanja na životinjama ukazuju na prijenos cetuksimaba kroz posteljicu kao i drugih IgG1 protutijela.
English: CRS is normally most severe in relation to the first infusion.
Croatian: Sindrom oslobađanja citokina je obično najteži kad je povezan s prvom infuzijom.
English: Chemotherapy must not be administered earlier than 1 hour after the end of the cetuximab infusion.
Croatian: Kemoterapija se ne smije primijeniti u vremenu kraćem od jednog sata nakon završetka infuzije cetuksimabom.
English: Take an appropriate sterile syringe and attach a suitable needle.
Croatian: Uzmite odgovarajuću sterilnu štrcaljku i na nju pričvrstite prikladnu iglu.
English: There is limited experience with single doses higher than 400 mg/m2 body surface area to date or weekly administrations of doses higher than 250 mg/m 2 body surface area.
Croatian: Iskustva s pojedinačnim dozama višim od 400 mg/m2 tjelesne površine ili tjedne primjene doza viših od 250 mg/m2 tjelesne površine su ograničena.
English: Of the KRAS mutant population, 297 patients received cetuximab and oxaliplatin plus fluoropyrimidines (101 patients OxMdG and 196 patients XELOX) and 268 patients received oxaliplatin plus fluoropyrimidines alone (78 patients OxMdG and 190 patients XELOX).
Croatian: Od populacije s mutiranim KRAS-om, 297 bolesnika primilo je cetuksimab i oksaliplatin s fluropirimidinima (101 bolesnik OxMdG i 196 bolesnika XELOX) a 268 bolesnika su primali samo oksaliplatin i fluoropirimidine (78 bolesnika OxMdG i 190 bolesnika XELOX).
English: • inflammation of the lining of the intestine and mouth
Croatian: • upala sluznice crijeva i usta
English: Connect the infusion line and prime it with the diluted Erbitux before starting the infusion.
Croatian: Spojite infuzijsku liniju i ispunite ju razrijeđenim Erbituxom prije započinjanja infuzije.
English: There were significant dose reductions and delays of capecitabine or oxaliplatin administration mainly due to higher frequency of diarrhoea in the cetuximab containing arm.
Croatian: Postojala je značajna redukcija doze i odgode u primjeni kapecitabina ili oksaliplatina uglavnom zbog veće učestalosti proljeva u skupini koja je primala cetuksimab.
English: Erbitux may be administered via a gravity drip, an infusion pump or a syringe pump.
Croatian: Erbitux se može primijeniti putem obične infuziije, infuzijske pumpe ili injekcijske pumpe.
English: • blood clots in the veins of the legs
Croatian: • krvni ugrušci u venama nogu
English: Squamous cell cancer of the head and neck
Croatian: Karcinom pločastih stanica glave i vrata
English: All subsequent weekly doses are 250 mg cetuximab per m2 each.
Croatian: Sve sljedeće tjedne doze su 250 mg cetuksimaba po m
English: KRAS wild-type population
Croatian: populacija „divljeg tipa“
English: Cetuximab in combination with platinum-based chemotherapy in recurrent and/or metastatic disease
Croatian: Cetuksimab u kombinaciji s kemoterapijom na bazi platine kod recidivirajuće i/ili metastatske bolesti
English: Determination of serum electrolyte levels is recommended prior to and periodically during cetuximab treatment.
Croatian: Kontrola elektrolita u serumu preporučuje se prije početka liječenja cetuksimabom te periodično, tijekom liječenja.
English: If you receive Erbitux with radiation therapy, some of the side effects you may experience can also be related to this combination, such as:
Croatian: Ako Erbitux primate u kombinaciji sa zračenjem, neke od nuspojava koje možete osjetiti također se odnose na kombinaciju, kao što su:
English: Colorectal cancer patients with RAS mutated tumours Cetuximab should not be used in the treatment of colorectal cancer patients whose tumours have RAS mutations or for whom RAS tumour status is unknown.
Croatian: Cetuksimab se ne smije koristiti za liječenje bolesnika s kolorektalnim karcinomom čiji tumori imaju RAS mutaciju ili kod kojih je RAS status tumora nepoznat.
English: In patients with recurrent and/or metastatic squamous cell cancer of the head and neck, cetuximab is used in combination with platinum-based chemotherapy followed by cetuximab as maintenance therapy until disease progression (see section 5.1).
Croatian: Kod bolesnika s rekurentnim i/ili metastatskim karcinomom pločastih stanica glave i vrata, cetuksimab se primjenjuje u kombinaciji s kemoterapijom na bazi platine koju slijedi cetuksimab kao terapija održavanja do progresije bolesti (vidjeti dio 5.1).
English: • breathing difficulties
Croatian: • poteškoće pri disanju
English: When prescribing cetuximab, the cardiovascular and performance status of the patients and concomitant administration of cardiotoxic compounds such as fluoropyrimidines should be taken into account.
Croatian: Kod propisivanja cetuksimaba potrebno je uzeti u obzir kardiovaskularni i opći status bolesnika te istovremenu primjenu kardiotoksičnih tvari kao što su fluoropirimidini.
English: Pre-treatment
Croatian: Predliječenje
English: In the KRAS wild-type population of the CALGB/SWOG 80405 study (n=1137), superiority of cetuximab plus chemotherapy over bevacizumab plus chemotherapy was not shown based on an interim analysis.
Croatian: Na temelju interim analize podataka iz ispitivanja 80405 CALGB/SWOG (n=1137) nije dokazana nadmoć cetuksimaba i kemoterapije nad bevacizumabom i kemoterapijom u populaciji s „divljim tipom“
English: It is recommended to start cetuximab therapy one week before radiation therapy and to continue cetuximab therapy until the end of the radiation therapy period.
Croatian: Preporučuje se liječenje cetuksimabom započeti jedan tjedan prije početka zračenja te liječenje cetuksimabom nastaviti do kraja zračenja.
English: No other formal interaction studies with cetuximab have been performed in humans.
Croatian: Druga formalna ispitivanja interakcija cetuksimaba kod ljudi nisu provedena.
English: The RAS mutant population consists of patients with known KRAS exon 2 mutations as well as additionally identified RAS mutations.
Croatian: Populacija s mutiranim RAS-om sastoji se od bolesnika s poznatim mutacijama eksona 2 KRAS-a, kao i s naknadno utvrđenim mutacijama RAS-a.
English: In these patients, Erbitux is used in combination with radiation therapy or with other anticancer medicines.
Croatian: Kod ovih se bolesnika Erbitux koristi u kombinaciji sa zračenjem ili drugim lijekovima za liječenje karcinoma.
English: In patients with metastatic colorectal cancer, cetuximab is used in combination with chemotherapy or as a single agent (see section 5.1).
Croatian: Kod bolesnika s metastatskim kolorektalnim karcinomom, cetuksimab se primjenjuje u kombinaciji s kemoterapijom ili kao samostalan lijek (vidjeti dio 5.1).
English: Erbitux may cause infusion-related side effects.
Croatian: Erbitux može uzrokovati nuspojave povezane s infuzijom.
English: Draw up the required volume of Erbitux from a vial.
Croatian: Izvucite potrebni volumen Erbituxa iz bočice.
English: • with polyethylene (PE), ethyl vinyl acetate (EVA) or polyvinyl chloride (PVC) bags,
Croatian: • vrećicama od polietilena (PE), etilvinilacetata (EVA) ili polivinilklorida (PVC),
English: Connect the infusion line to the syringe, set and control the rate as explained in section 4.2 and start the infusion after priming the line with Erbitux or sterile sodium chloride 9 mg/mL (0.9%) solution.
Croatian: Spojite infuzijsku liniju na štrcaljku, postavite i kontrolirajte brzinu kako je objašnjeno u dijelu 4.2 te započnite infuziju nakon što se linija ispuni Erbituxom ili 0,9%-tnom (9 mg/ml) sterilnom otopinom natrijeva klorida.
English: • The other ingredients are sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide and water for injections.
Croatian: • Drugi sastojci su: natrijev klorid, glicin, polisorbat 80, citratna kiselina hidrat, natrijev hidroksid i voda za injekcije.
English: Patients who receive cetuximab in combination with platinum-based chemotherapy are at an increased risk for the occurrence of severe neutropenia, which may lead to subsequent infectious complications such as febrile neutropenia, pneumonia or sepsis.
Croatian: Kod bolesnika koji primaju cetuksimab u kombinaciji s kemoterapijom na bazi platine povećan je rizik od pojave teške neutropenije koja može voditi do daljnjih infekcijskih komplikacija kao što su febrilna neutropenija, pneumonija ili sepsa.
English: Cetuximab also targets cytotoxic immune effector cells towards EGFRexpressing tumour cells (antibody dependent cell-mediated cytotoxicity, ADCC).
Croatian: Cetuksimab također usmjerava citotoksične imunološke efektorske stanice prema tumorskim stanicama koje iskazuju EGFR (stanično posredovana citotoksičnost ovisna o protutijelu, ADCC).
English: • drying out which may be due to diarrhoea or reduced fluid intake
Croatian: • dehidracija zbog proljeva ili smanjenog unosa tekućine
English: Each subsequent dose (250 mg/m² body surface area) is infused in approximately 1 hour with an infusion rate not faster than 10 mg/min.
Croatian: Svaka sljedeća doza je 250 mg/m² tjelesne površine u infuziji koja traje otprilike 1 sat pri brzini infuzije ne većoj od 10 mg/min.
English: They must not be administered earlier than 1 hour after the end of the cetuximab infusion.
Croatian: Oni se ne smiju primijeniti u vremenu kraćem od jednog sata nakon kraja infuzije cetuksimaba.
English: Use a gravity drip or an infusion pump for administration.
Croatian: Za primjenu koristite običnu infuziju ili infuzijsku pumpu.
English: Skin reactions are very common and treatment interruption or discontinuation may be required.
Croatian: Kožne reakcije su vrlo česte te mogu iziskivati privremeni ili trajni prekid liječenja.
English: In all indications, Erbitux is administered once a week.
Croatian: Erbitux se kod svih indikacija primjenjuje jednom tjedno.
English: • The active substance is cetuximab.
Croatian: • Djelatna tvar je cetuksimab.
English: FIRE-3 (First-line combination of cetuximab with FOLFIRI): The FIRE-3 study was a multicentre randomised phase-III study investigating head-to-head 5-FU, folinic acid and irinotecan (FOLFIRI) combined with either cetuximab or bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC).
Croatian: FIRE-3 (Kombinacija cetuksimaba s FOLFIRI-jem u prvoj liniji liječenja): Ispitivanje FIRE-3 bilo je multicentrično, randomizirano ispitivanje faze III u kojem je izravno uspoređeno liječenje 5-FU, folnom kiselinom i irinotekanom (FOLFIRI) u kombinaciji ili s cetuksimabom ili s bevacizumabom u bolesnika s metastatskim kolorektalnim karcinomom (mCRC) s „divljim tipom“ eksona 2 KRAS-a.
English: • EMR 62 202-006: This randomised study compared the combination of cetuximab and radiation therapy (211 patients) with radiation therapy alone (213 patients) in patients with locally advanced squamous cell cancer of the head and neck.
Croatian: • EMR 62 202-006: Ovo randomizirano ispitivanje usporedilo je kombinaciju cetuksimaba i zračenja (211 bolesnika) sa zračenjem samim (213 bolesnika) kod bolesnika s lokalno uznapredovalim karcinomom pločastih stanica glave i vrata.
English: FIRE-3, an investigator-sponsored clinical phase-III study, compared the treatment of FOLFIRI in combination with either cetuximab or bevacizumab in the first-line treatment of patients with KRAS exon 2 wild-type mCRC.
Croatian: U FIRE-3, kliničkom ispitivanju faze III koje su sponzorirali ispitivači, uspoređivano je liječenje FOLFIRI-jem u kombinaciji ili s cetuksimabom ili s bevacizumabom u prvoj liniji liječenja bolesnika s mCRC s „divljim tipom“ eksona 2 KRAS-a.
English: What Erbitux is
Croatian: Što je Erbitux
English: • For administration with a syringe pump: Calculate the required volume of Erbitux.
Croatian: • Za primjenu s injekcijskom pumpom: Izračunajte potrebni volumen Erbituxa.
English: In contrast to progression free survival time, no benefit in overall survival time could be demonstrated in patients with KPS ≤ 80 who were 65 years of age or older.
Croatian: Suprotno vremenu preživljenja bez napredovanja bolesti, kod bolesnika s KPS ≤ 80, starosti 65 godina i starijih, nije se mogla dokazati korist u ukupnom vremenu preživljenja.
English: No non-clinical data on the effect of cetuximab on wound healing are available to date.
Croatian: Do danas nema nekliničkih podataka o učinku cetuksimaba na zacjeljivanje rana.
English: In patients with locally advanced squamous cell cancer of the head and neck, cetuximab is used concomitantly with radiation therapy.
Croatian: Kod bolesnika s lokalno uznapredovalim karcinomom pločastih stanica glave i vrata, cetuksimab se primjenjuje u kombinaciji sa zračenjem.
English: Cetuximab plus OxMdG
Croatian: Cetuksimab i OxMdG
English: The first dose (400 mg/m² body surface area) is infused over a period of approximately 2 hours with an infusion rate not faster than 5 mg/min.
Croatian: Prva je doza 400 mg/m² tjelesne površine u infuziji koja traje otprilike 2 sata pri brzini infuzije ne većoj od 5 mg/min.
English: If a diagnosis of ulcerative keratitis is confirmed, treatment with cetuximab should be interrupted or discontinued.
Croatian: U slučaju potvrđene dijagnoze ulceroznog keratitisa liječenje cetuksimabom treba privremeno ili trajno prekinuti.
English: Confounding or contributing factors, such as concomitant chemotherapy known to be associated with ILD, and pre-existing pulmonary diseases were frequent in fatal cases.
Croatian: U slučajevima sa smrtnim ishodom često su bili prisutni zbunjujući faktori ili faktori koji doprinose razvoju bolesti, kao što je istodobno primijenjena kemoterapija za koju je poznato da je povezana s ILD-om, te prethodno postojeće bolesti pluća.
English: Evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with Erbitux.
Croatian: Prije početka liječenja Erbituxom potrebno je potvrditi RAS (KRAS i NRAS) status „divljeg tipa“.
English: Patients with a good prognosis as indicated by tumour stage, Karnofsky performance status (KPS) and age had a more pronounced benefit, when cetuximab was added to platinum-based chemotherapy.
Croatian: Bolesnici s dobrom prognozom, s obzirom na stadij tumora, opći status prema Karnofskom (KPS) te dob, imali su mnogo izraženiju korist kada je kemoterapiji na bazi platine dodan cetuksimab.
English: In some studies association with age ≥ 65 years or performance status has been observed.
Croatian: U nekim je ispitivanjima opažena povezanost s dobi bolesnika ≥ 65 godina te općim statusom.
English: In combination with fluoropyrimidines, the frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome (palmar-plantar erythrodysaesthesia) were increased compared to that with fluoropyrimidines.
Croatian: U kombinaciji s fluoropirimidinima, u odnosu na samostalnu primjenu fluoropirimidina, povećala se učestalost ishemije srca, uključujući infarkt miokarda, kongestivno zatajivanje srca kao i učestalost sindroma šake i stopala (palmarno-plantarne eritrodisestezije).
English: Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)expressing, RAS wild-type metastatic colorectal cancer
Croatian: Erbitux je indiciran za liječenje bolesnika s metastatskim kolorektalnim karcinomom koji iskazuje receptor za epidermalni čimbenik rasta (EGFR) s „divljim tipom“ gena RAS
English: If you receive Erbitux in combination with other anticancer medicines, some of the side effects you may experience can also be related to the combination or the other medicines.
Croatian: Ako Erbitux primate u kombinaciji s drugim lijekovima za liječenje karcinoma, neke nuspojave koje ćete možda osjetiti mogu biti povezane s kombinacijom lijekova ili drugim lijekom.
English: Cetuximab plus BSC
Croatian: Cetuksimab i BSC
English: • platelet count < 100000/mm³
Croatian: • broj trombocita < 100 000/mm³
English: No new safety signals were identified in paediatric patients as reported from a phase-I study.
Croatian: Prema izvješćima ispitivanja faze I nisu identificirani novi sigurnosni signali u pedijatrijskih bolesnika.
English: METHOD AND ROUTE(S) OF ADMINISTRATION Intravenous use.
Croatian: NAČIN I PUT(EVI) PRIMJENE LIJEKA Za intravensku primjenu.
English: Common side effects (may affect up to 1 in 10 people)
Croatian: Česte nuspojave (mogu se pojaviti kod do 1 na 10 osoba)
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/281/003
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/04/281/003
English: Further post-hoc analyses on mutations on RAS genes other than KRAS exon 2 have been evaluated.
Croatian: Procijenjene su i dodatne post hoc analize drugih mutacija RAS gena osim onih na eksonu 2 KRAS-a.
English: If you receive Erbitux in combination with other anticancer medicines, including fluoropyrimidines, it may be more likely that you experience heart problems which may be life-threatening.
Croatian: Ako primate Erbitux u kombinaciji s drugim lijekovima protiv karcinoma, uključujući i fluoropirimidine, vjerojatnije da ćete iskusiti po život opasne probleme sa srcem.
English: Respiratory disorders
Croatian: Poremećaji disanja
English: OS months, median (95% CI) Hazard Ratio (95% CI) p-value PFS months, median (95% CI) Hazard Ratio (95% CI) p-value ORR % (95% CI) p-value CI = confidence interval, CTX = platinum-based chemotherapy, ORR = objective response rate, OS = overall survival time, PFS = progression-free survival time
Croatian: OS mjeseci, medijan (95% CI) Omjer hazarda (95% CI) p-vrijednost PFS mjeseci, medijan (95% CI) Omjer hazarda (95% CI) p-vrijednost ORR % (95% CI) p-vrijednost CI = interval pouzdanosti; CTX = (platinum-based chemotherapy) kemoterapija na bazi platine; ORR (objective response rate) = objektivna stopa odgovora; OS (overal survival time) = ukupno vrijeme preživljenja; PFS (progression-free survival time) = vrijeme preživljenja bez napredovanja bolesti
English: Your doctor may consider reducing the infusion rate of Erbitux to manage these symptoms.
Croatian: Za umanjenje simptoma liječnik može razmotriti smanjenje brzine infuzije Erbituxa.
English: Patients with a good prognosis as indicated by tumour stage, Karnofsky performance status (KPS) and age had a more pronounced benefit, when cetuximab was added to radiation therapy.
Croatian: Bolesnici s dobrom prognozom, s obzirom na stadij tumora, opći status prema Karnofskom (KPS) te dob, imali su mnogo izraženiju korist kada je cetuksimab dodan zračenju.
English: EGFR is involved in foetal development.
Croatian: Receptor za epidermalni čimbenik rasta (EGFR) uključen je u razvoj fetusa.
English: A separate infusion line must be used for the infusion, and the line must be flushed with sterile sodium chloride 9 mg/mL (0.9%) solution for injection at the end of infusion.
Croatian: Za infuziju se mora koristiti zasebna infuzijska linija koja se na kraju infuzije mora isprati 0,9%-tnom (9 mg/ml) sterilnom otopinom natrijeva klorida za injekciju.
English: A diagnostic assay (EGFR pharmDx) was used for immunohistochemical detection of EGFR expression in tumour material.
Croatian: Za imunohistokemijsko određivanje ekspresije EGFR u tumorskom materijalu korišten je dijagnostički test (EGFR pharmDx).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial of 20 mL contains 100 mg cetuximab (5 mg/mL).
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna bočica od 20 ml sadrži 100 mg cetuksimaba (5 mg/ml).
English: Each vial of 100 mL contains 500 mg cetuximab (5 mg/mL).
Croatian: Jedna bočica od 100 ml sadrži 500 mg cetuksimaba (5 mg/ml).
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 29/06/2004
Croatian: Datum prvog odobrenja: 29.06.2004.
English: Uncommon side effects (may affect up to 1 in 100 people)
Croatian: Manje česte nuspojave (mogu se pojaviti kod do 1 na 100 osoba)
English: What Erbitux is used for
Croatian: Za što se Erbitux koristi
English: Erbitux contains cetuximab, a monoclonal antibody.
Croatian: Erbitux sadrži monoklonsko protutijelo cetuksimab.
English: If you receive Erbitux in combination with an anticancer medicine containing fluoropyrimidines, it is more likely that you experience the following side effects of this other medicine:
Croatian: Ako Erbitux primate u kombinaciji s lijekom za liječenje karcinoma koji sadrži fluoropirimidine, vjerojatnije je da ćete dobiti sljedeće nuspojave vezane uz ovaj drugi lijek: